Ipsen’s R&D activities are focused on the discovery and development of new molecules and on programs for the life cycle management of products already marketed by the group (new formulations, extension of indications and registration of products in new geographical areas)

In 2011, Ipsen’s R&D expenditure totaled more than €250 million, representing close to 22% of sales.